Please use this identifier to cite or link to this item: http://ahro.austin.org.au/austinjspui/handle/1/11548
Title: Syndrome of inappropriate anti-diuretic hormone secretion secondary to carboplatin after docetaxel-carboplatin-trastuzumab combination for early stage HER-2 positive breast cancer.
Authors: Turner, Natalie;Stewart, Josephine;Barnett, Frances;White, Shane C
Affiliation: The Northern Hospital Austin Hospital, Melbourne, Victoria, Australia. nhturner@hotmail.com
Issue Date: 2-May-2012
Citation: Asia-pacific Journal of Clinical Oncology 2012; 8(3): e9-e11
Abstract: Carboplatin is a platinum analogue, widely used in the treatment of numerous cancer types including lung, genitourinary and ovarian cancers. It is also used in the adjuvant treatment of human epidermal growth factor receptor 2 positive breast cancer, where a non-anthracycline regimen is preferred. It is considered generally to be less toxic though potentially less efficacious than cisplatin, another platinum compound. Cisplatin is well recognized as causing hyponatremia, through the mechanism of renal salt wasting. Conversely, carboplatin has only rarely been associated with hyponatremia. We report here a case of severe hyponatremia occurring 6 days after adjuvant treatment with a carboplatin-containing chemotherapy regimen for early stage breast cancer. The mechanism of hyponatremia was consistent with the syndrome of inappropriate anti-diuretic hormone secretion based on biochemical and clinical findings, and response to fluid restriction. With no previously reported cases of docetaxel-associated or trastuzumab-associated hyponatremia, the causative agent was considered to be carboplatin. Additionally there was no recurrence of hyponatremia on recommencement of docetaxel and trastuzumab therapy. Hyponatremia secondary to carboplatin has been rarely reported in the literature, with only three previously reported cases. Although it is rare, oncologists should be aware of the potential for carboplatin to cause hyponatremia and the need to monitor electrolytes throughout therapy.
Internal ID Number: 22897880
URI: http://ahro.austin.org.au/austinjspui/handle/1/11548
DOI: 10.1111/j.1743-7563.2012.01526.x
URL: http://www.ncbi.nlm.nih.gov/pubmed/22897880
Type: Journal Article
Subjects: Antibodies, Monoclonal, Humanized.administration & dosage.adverse effects
Antineoplastic Combined Chemotherapy Protocols.adverse effects.therapeutic use
Breast Neoplasms.blood.drug therapy.enzymology
Carboplatin.administration & dosage.adverse effects
Female
Humans
Hyponatremia.chemically induced.enzymology
Inappropriate ADH Syndrome.chemically induced.enzymology
Middle Aged
Receptor, ErbB-2.metabolism
Taxoids.administration & dosage.adverse effects
Appears in Collections:Journal articles

Files in This Item:
There are no files associated with this item.


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.